Minimising neonatal brain injury: how research in the past five years has changed my clinical practice.
With improving neonatal survival for extremely premature babies, the challenge for neonatology is to improve outcome of surviving babies. This review concentrates on best evidence emerging in recent years on prevention of brain damage by early administration of drugs as well as avoidance of induced brain damage by hyperventilation and dexamethasone therapy given postnatally for chronic lung disease.
Levene
Malcolm
M
Academic Department of Paediatrics, D Floor, Clarendon Wing, University of Leeds, Leeds General Infirmary, Leeds LS2 9NS, UK. m.i.levene@leeds.ac.uk
D000818:Animals; D001720:Birth Injuries / Q000517:prevention & control*; D001927:Brain Diseases / Q000151:congenital / Q000517:prevention & control*; D003907:Dexamethasone / Q000627:therapeutic use; D004195:Disease Models, Animal; D004979:Ethamsylate / Q000627:therapeutic use; D006801:Humans; D016857:Hypocapnia / Q000150:complications / Q000188:drug therapy; D007213:Indomethacin / Q000627:therapeutic use; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D008171:Lung Diseases / Q000151:congenital / Q000517:prevention & control; D010634:Phenobarbital / Q000627:therapeutic use
D004979:Ethamsylate; D003907:Dexamethasone; D007213:Indomethacin; D010634:Phenobarbital